BioAtla, Inc. (BCAB) Bundle
An Overview of BioAtla, Inc. (BCAB)
General Summary of BioAtla, Inc. (BCAB)
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumors. Founded in 2012, the company specializes in its proprietary CAB (Conditional Antibody) technology, which enables the targeting of tumor-specific antigens in a selective manner, aiming to minimize damage to healthy tissues. As of 2024, BioAtla's product pipeline includes several promising candidates: Mecbotamab vedotin (BA3011), Ozuriftamab vedotin (BA3021), Evalstotug (BA3071), and BA3182. The company has entered into various collaborations to bolster its research and development efforts.
In terms of sales, BioAtla reported collaboration and other revenue of $11.0 million for the nine months ended September 30, 2024, which is attributed to its Context License Agreement. This marks a significant milestone in their revenue generation strategy.
Company's Financial Performance in the Latest Financial Reports
BioAtla's financial performance for the nine months ended September 30, 2024, reflects a noteworthy trajectory despite ongoing net losses. The company reported a net loss of $54.9 million for this period compared to a loss of $96.5 million in the same period of 2023, indicating an improvement of approximately 43% year-over-year. The total operating expenses for the nine months were $68.7 million, down from $101.2 million in 2023, driven primarily by a decrease in research and development expenses.
The following table summarizes key financial statistics for BioAtla:
| Financial Metric | 2024 (Nine Months Ended September 30) | 2023 (Nine Months Ended September 30) | Change |
|---|---|---|---|
| Net Loss | $54.9 million | $96.5 million | Improvement of $41.6 million |
| Total Operating Expenses | $68.7 million | $101.2 million | Reduction of $32.5 million |
| Collaboration and Other Revenue | $11.0 million | $0 | Increase of $11.0 million |
| Cash and Cash Equivalents | $56.5 million | $141.3 million | Decrease of $84.8 million |
Research and development expenses decreased significantly to $51.4 million in 2024 from $81.1 million in 2023, primarily due to reduced costs in clinical trials and external expenses.
Introduction to BioAtla, Inc. as a Leader in the Industry
BioAtla, Inc. is recognized as a leader in the biopharmaceutical industry, particularly for its innovative approaches to cancer treatment. The company's focus on CAB technology distinguishes it from competitors by providing a platform capable of targeting cancer cells more effectively while minimizing adverse effects on healthy tissues. BioAtla's strategic partnerships and collaborations have further positioned it as a frontrunner in developing next-generation therapeutics for solid tumors. With a strong commitment to advancing its product pipeline and enhancing its scientific capabilities, BioAtla is poised to make significant strides in the biopharmaceutical landscape.
Mission Statement of BioAtla, Inc. (BCAB)
Mission Statement of BioAtla, Inc. (BCAB)
BioAtla, Inc. (BCAB) is dedicated to developing innovative therapeutics for the treatment of solid tumors through its proprietary platform of conditionally active biologics (CABs). The mission statement serves as a guiding principle for the company’s strategic objectives and operational focus, emphasizing their commitment to improving patient outcomes in oncology.
Core Component 1: Innovation in Cancer Treatment
BioAtla’s mission underscores a strong commitment to innovation in cancer therapeutics. The company specializes in developing CABs, which are designed to be active only in the tumor microenvironment, minimizing damage to healthy tissues. This innovative approach aims to enhance the efficacy and safety profiles of cancer treatments.
For instance, in the nine months ended September 30, 2024, BioAtla reported research and development expenses totaling $51.4 million, reflecting their ongoing commitment to advancing their innovative product pipeline. The company’s lead product candidates include:
| Product Candidate | Target | Development Stage |
|---|---|---|
| Mecbotamab vedotin (BA3011) | AXL | Phase 2 |
| Ozuriftamab vedotin (BA3021) | ROR2 | Phase 2 |
| Evalstotug (BA3071) | CTLA-4 | Phase 1 |
| BA3182 | EpCAM x CD3 | Phase 1 |
Core Component 2: Commitment to High-Quality Products
Another essential component of BioAtla's mission is the commitment to delivering high-quality therapeutic products. The company focuses on rigorous research and development processes to ensure that their products meet stringent regulatory standards.
In 2024, BioAtla recognized collaboration and other revenue of $11.0 million from a licensing agreement, indicating successful partnerships that support their mission by facilitating the development of high-quality therapeutics. The focus on quality is reflected in their significant investment in R&D, which accounted for approximately 75% of their total operating expenses in the same period.
Core Component 3: Patient-Centric Approach
BioAtla's mission statement emphasizes a patient-centric approach, aiming to improve the quality of life for individuals affected by cancer. This is evident in their strategic initiatives and product development that prioritize patient needs and treatment outcomes.
As of September 30, 2024, the company reported an accumulated deficit of $471.2 million, which highlights the substantial investments made toward developing therapies that could ultimately benefit patients. BioAtla's pipeline is designed not only to target cancer effectively but also to reduce the adverse effects commonly associated with traditional cancer therapies, aligning with their mission to enhance patient care.
With a focus on advancing their CAB technology platform, BioAtla aims to address unmet medical needs in oncology, demonstrating a strong alignment with their mission to innovate and improve cancer treatment.
Vision Statement of BioAtla, Inc. (BCAB)
Vision Statement of BioAtla, Inc. (BCAB)
BioAtla, Inc. aims to revolutionize cancer treatment through its innovative approach to creating conditionally active biologics (CABs). The vision is to develop highly specific and selective antibody-based therapeutics that target solid tumors, leveraging unique tumor biology insights.
Key Components of the Vision StatementInnovation in Therapeutics
BioAtla is committed to pioneering new therapies that harness the unique characteristics of tumor environments, particularly their acidic conditions. The company is focused on advancing its lead product candidates, including:
- Mecbotamab vedotin (BA3011), targeting AXL
- Ozuriftamab vedotin (BA3021), targeting ROR2
- Evalstotug (BA3071), targeting CTLA-4
- BA3182, a bispecific antibody targeting EpCAM x CD3
As of September 30, 2024, BioAtla reported total research and development expenses of approximately $51.4 million, showcasing its dedication to innovation and development.
Commitment to Patient-Centric Solutions
BioAtla envisions a future where its therapies significantly improve patient outcomes by minimizing off-target toxicity. The focus is on delivering treatments that are effective yet safe for patients, thus enhancing the quality of life for those battling cancer.
Strategic Collaborations
The company recognizes the importance of partnerships in accelerating its development process. In September 2024, BioAtla entered a licensing agreement with Context Therapeutics, which generated $11 million in revenue for the three months ended September 30, 2024. Such collaborations are vital in expanding its reach and resources.
Financial Sustainability
To support its vision, BioAtla aims to secure substantial capital for ongoing operations. As of September 30, 2024, the company had cash and cash equivalents amounting to $56.5 million. This financial foundation is critical for funding research, clinical trials, and potential commercialization of its therapies.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Research and Development Expenses | $51.4 million | $81.1 million | Decrease of $29.6 million |
| General and Administrative Expenses | $17.3 million | $20.1 million | Decrease of $2.8 million |
| Net Loss | $54.9 million | $96.5 million | Decrease of $41.6 million |
| Collaboration Revenue | $11 million | $0 | Increase of $11 million |
| Cash and Cash Equivalents | $56.5 million | $141.3 million | Decrease of $84.8 million |
Future Growth and Development
BioAtla envisions expanding its pipeline of CAB candidates, continuing to innovate within the biopharmaceutical space. The company expects ongoing clinical trials and research to drive future growth, with a focus on obtaining regulatory approvals for its product candidates.
With a strategic focus on innovation, collaboration, and patient-centric solutions, BioAtla, Inc. is poised to make significant contributions to cancer therapeutics. Its vision for 2024 and beyond underscores a commitment to transforming the landscape of cancer treatment through advanced biologics.
Core Values of BioAtla, Inc. (BCAB)
Integrity
Integrity is the cornerstone of BioAtla's operations, emphasizing honesty and transparency in all business practices. This value fosters trust among stakeholders, including employees, partners, and investors.
In 2024, BioAtla demonstrated integrity through its transparent reporting practices, including the detailed disclosures in its quarterly financial statements. For example, the company reported a net loss of $54.9 million for the nine months ended September 30, 2024, a decrease from $96.5 million in the same period of 2023, showcasing its commitment to honest communication about financial performance.
Innovation
Innovation drives BioAtla's mission to develop cutting-edge antibody-based therapeutics for cancer treatment. The company invests heavily in research and development to pioneer novel therapies.
For instance, in the nine months ended September 30, 2024, BioAtla allocated $51.4 million to research and development, a significant reduction from $81.1 million in 2023. This strategic allocation reflects an ongoing commitment to enhancing its product pipeline, which includes candidates like mecbotamab vedotin and ozuriftamab vedotin.
Collaboration
Collaboration is essential for BioAtla, enabling the company to leverage partnerships for advancing its therapeutic candidates. This core value fosters synergies that enhance research capabilities and market reach.
In September 2024, BioAtla entered into a Global Transaction Agreement with Himalaya Therapeutics, allowing for shared resources and expertise in clinical trials. This partnership is part of BioAtla's strategy to expand its operational capabilities and expedite the clinical development of its products.
Excellence
Excellence is a guiding principle for BioAtla, reflected in its commitment to high-quality standards in research, development, and operations. The company strives to exceed expectations in all areas of its business.
BioAtla's operational excellence is evident in its clinical trial processes. The company completed Phase 2 enrollment for its ongoing antibody-drug conjugate trials, demonstrating efficiency and effectiveness in its clinical development efforts.
Accountability
Accountability is integral to BioAtla's culture, ensuring that all employees take responsibility for their actions and decisions. This core value promotes a results-oriented environment where performance is regularly assessed.
As of September 30, 2024, BioAtla reported an accumulated deficit of $471.2 million, underscoring the financial challenges the company faces. The management's accountability in addressing these challenges is crucial for future success.
| Core Value | Description | 2024 Data Point |
|---|---|---|
| Integrity | Honesty and transparency in operations | Net loss of $54.9 million for the nine months ended September 30, 2024 |
| Innovation | Commitment to developing new therapies | $51.4 million allocated to R&D for the nine months ended September 30, 2024 |
| Collaboration | Partnerships to enhance capabilities | Global Transaction Agreement with Himalaya Therapeutics in September 2024 |
| Excellence | High standards in all business areas | Completion of Phase 2 enrollment in ongoing trials |
| Accountability | Responsibility for actions and decisions | Accumulated deficit of $471.2 million as of September 30, 2024 |
BioAtla, Inc. (BCAB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- BioAtla, Inc. (BCAB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of BioAtla, Inc. (BCAB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View BioAtla, Inc. (BCAB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.